sub:assertion {
  drugbank:DB01104 a biolink:Drug ;
    rdfs:label "sertraline" ;
    biolink:category biolink:Drug .
  mondo:0008114 a biolink:Disease ;
    rdfs:label "obsessive-compulsive disorder" ;
    biolink:category biolink:Disease .
  sub:association rdf:object mondo:0008114 ;
    rdf:predicate biolink:treats ;
    rdf:subject drugbank:DB01104 ;
    a biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    rdfs:label "Sertraline has shown efficacy and safety at doses of 50-200 mg/day [72] in treating phobic-related states, with a greater reduction in symptoms related to anxiety/fear, physical symptoms and avoidance behaviors [73]. Clinical improvements in obsessive symptoms and phobic behavior have been achieved with long-term therapy, with a good tolerability profile. A rapid sertraline titration up to 200 mg/day correlated with fast response rates. A 20-week study with sertraline 50-200 mg/day produced significant improvements both in functioning and social skills [74]. Stable sertraline treatment guaranteed lower recurrence rates, and a general improvement in quality of life. Placebo-controlled studies consistently showed sertraline-related treatment response [72, 75, 76], although with one exception [77]. Treatment of refractory OCD with high doses of sertraline (250-400 mg/day) resulted in a significant symptom improvement and a similar rate of adverse events observed with a 200 mg/day dose [78]." ;
    biolink:aggregator_knowledge_source infores:knowledge-collaboratory ;
    biolink:category biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    biolink:has_population_context sub:context ;
    biolink:publications pmid:30101713 ;
    biolink:relation ncit:C94303 .
  sub:context a biolink:Cohort ;
    rdfs:label "adults" ;
    biolink:category biolink:Cohort .
}